Invalidity dossier
US 5994616
Targeted synthesis of protein in mammary gland of a non-human transgenic mammal
Current assignee: Pharming Intellectual Property BV
Added 9/23/2026, 9:06:35 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 5,994,616
Title: "Targeted synthesis of protein in mammary gland of a non-human transgenic mammal" (as given).
Patent number / application: US 5,994,616 A; application US 08/186,836.
Inventor: Jeffrey M. Rosen (listed as inventor; the record also shows an assignment from Rosen to Baylor College of Medicine).
Assignee: Original assignee listed as Pharming BV. The record shows a chain of recorded reassignments, ending with "Current Assignee" listed as Pharming Intellectual Property BV. Security interests and releases involving King George Holdings Luxembourg IIA S.à r.l., Silicon Valley Bank, and Orbimed Royalty Opportunities II, LP also appear.
Key dates: Priority date 1987-02-17; filing date 1994-01-25; publication/grant 1999-11-30; anticipated expiration 2016-11-30; legal status "Expired – Lifetime."
Purpose and plain-language scope (from the supplied text): The invention concerns producing a protein in the milk (mammary gland) of a non-human transgenic mammal, i.e., an animal genetically modified to make a chosen protein in its milk. Classification data point to casein (C07K14/4732) and casein-related "prior art keywords" (gene, casein, DNA, biologically active, active protein), indicating the mammary-gland-specific casein regulatory elements as the targeting/expression component, with transgenic mammals including mammals generally, murine and swine specifically. Also classified for resulting milk/dietetic milk preparations.
Source: https://patents.google.com/patent/US5994616/en
What the excerpt does not establish: It contains no claims, abstract, specification, examples, or sequence information, so the exact claimed scope, expressed protein(s), vector constructs, and method steps cannot be stated. Assignee and legal-status entries are expressly described as assumptions/not legal conclusions, and the excerpt does not establish ownership, validity, enforceability, or prior art. No litigation is assessed.
Generated 10/1/2026, 9:40:57 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5994616. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.